arrow
M

María Teresa Gómez-Casares

universidad de las palmas de grancanaria
H指数:30
被引数:3,438

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Survival outcomes and treatment patterns in myelofibrosis in the JAK inhibitor era

JAK抑制剂时代骨髓纤维化的生存结局与治疗模式

2026-08-210
PREAI
TRANSFORM-1 Phase 3 study: Efficacy and safety of navitoclax plus ruxolitinib in patients with untreated myelofibrosis

TRANSFORM-1 III期研究:纳维托克司联合鲁索利替尼在初治骨髓纤维化患者中的有效性和安全性

Blood
IF23.1
2026-07-020
PRE
Impact of thrombosis on disease progression, cancer and mortality in patients with essential thrombocythemia and polycythemia vera

血栓形成对原发性血小板增多症和真性红细胞增多症患者疾病进展、癌症和死亡率的影响

2026-05-010
OA
Response to therapy and prognosis according to molecular characterization in CALR-mutated essential thrombocythemia

CALR突变型原发性血小板增多症的分子特征与治疗反应及预后

2026-03-230
OAAI
The germline challenge in allogeneic transplantation: from donor selection to outcomes

同种异体移植中的种系挑战:从供体选择到结局

2026-03-040
PRE
Interlaboratory cross validation of acute myeloid leukemia fusion genes and mutational targets detected by PCR: Performance of PETHEMA central laboratories

实验室间交叉验证由PCR检测到的急性髓系白血病融合基因和突变靶点:PETHEMA中心实验室的表现

2025-12-010
PRE
Coexisting Myeloproliferative and Lymphoid Neoplasms: A European Multicenter Retrospective Study

共存骨髓增殖性肿瘤和淋巴性肿瘤:一项欧洲多中心回顾性研究

2025-10-170
OAAI
ADORE: an open platform study of ruxolitinib in combination with other novel therapies in patients with myelofibrosis

ADORE:一项关于鲁索利替尼与其他新型疗法联合治疗骨髓纤维化患者的开放平台研究

2025-05-090
OAAI
Real world outcomes of momelotinib in myelofibrosis patients with anemia: results from the MOMGEMFIN study

momelotinib在伴有贫血的骨髓纤维化患者中的真实世界结局:MOMGEMFIN研究的结果

2025-04-171
OA
Molecular response with asciminib 20 mg QD in a patient intolerant to multiple TKIs

对多种TKIs不耐受的患者使用asciminib 20 mg QD的分子反应

2025-04-010
OAAI
Real-World Outcomes of Momelotinib As an Alternative Therapy to Other JAK Inhibitors in Myelofibrosis Patients with Anemia

momelotinib 作为替代其他 JAK 抑制剂在贫血性骨髓纤维化患者中的真实世界疗效

BLOOD
IF23.1
2024-11-051
PRE
Prognostic Value of Response to First-Line Hydroxyurea According to Ipset Stratification in Essential Thrombocythemia

根据Ipset分层,对原发性血小板增多症患者一线羟基脲治疗反应的预后价值

BLOOD
IF23.1
2024-11-050
PRE
Characteristics of Pediatric and Adolescents and Young Adults (AYA) with Chronic Myeloid Leukemia: Data from the Canarian Registry of CML

儿科、青少年和年轻成人(AYA)慢性髓性白血病患者的特征:来自加那利慢性髓性白血病登记数据库的数据

BLOOD
IF23.1
2024-11-050
PRE
Prognostic value of response to first-line hydroxyurea according to IPSET stratification in essential thrombocythemia
LEUKEMIA
IF13.4
2024-09-270
PRE
Impact of somatic gene mutations on the risk of thrombosis in myelofibrosis
LEUKEMIA
IF13.4
2024-08-300
PRE
Evolving patterns and clinical outcome of genetic studies performed at diagnosis in acute myeloid leukemia patients: Real life data from the PETHEMA Registry
CANCER
IF5.1
2024-06-191
PRE
Validation of mutated CEBPA bZIP as a distinct prognosis entity in acute myeloid leukemia: a study by the Spanish PETHEMA registry
2024-04-180
OAAI
Hepatotoxicity as dose-limiting toxicity of the combination of bosutinib and atezolizumab in patients with chronic myeloid leukemia. Results of the ZEROLMC study
2024-04-031
PRE